|
1.
|
Leon X, Hitt R, Constenla M, et al: A
retrospective analysis of the outcome of patients with recurrent
and/or metastatic squamous cell carcinoma of the head and neck
refractory to a platinum-based chemotherapy. Clin Oncol.
17:418–424. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Carpenter G and Cohen S: Epidermal growth
factor. J Biol Chem. 265:7709–7712. 1990.
|
|
3.
|
Mendelsohn J and Baselga J: The EGF
receptor family as targets for cancer therapy. Oncogene.
19:6550–6565. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Grandis JR and Tweardy DJ: Elevated levels
of transforming growth factor alpha and epidermal growth factor
receptor messenger RNA are early markers of carcinogenesis in head
and neck cancer. Cancer Res. 53:3579–3584. 1993.PubMed/NCBI
|
|
5.
|
Santini J, Formento JL, Francoual M, et
al: Characterization, quantification, and potential clinical value
of the epidermal growth factor receptor in head and neck squamous
cell carcinomas. Head Neck. 13:132–139. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Bonner JA, Harari PM, Giralt J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Cohen EE, Rosen F, Stadler WM, et al:
Phase II trial of ZD1839 in recurrent or metastatic squamous cell
carcinoma of the head and neck. J Clin Oncol. 21:1980–1987. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Soulieres D, Senzer NN, Vokes EE, Hidalgo
M, Agarwala SS and Siu LL: Multicenter phase II study of erlotinib,
an oral epidermal growth factor receptor tyrosine kinase inhibitor,
in patients with recurrent or metastatic squamous cell cancer of
the head and neck. J Clin Oncol. 22:77–85. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Sen M, Joyce S, Panahandeh M, et al:
Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin
Cancer Res. 18:4986–4996. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Koppikar P, Choi SH, Egloff AM, et al:
Combined inhibition of c-Src and epidermal growth factor receptor
abrogates growth and invasion of head and neck squamous cell
carcinoma. Clin Cancer Res. 14:4284–4291. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Xu H, Stabile LP, Gubish CT, Gooding WE,
Grandis JR and Siegfried JM: Dual blockade of EGFR and c-Met
abrogates redundant signaling and proliferation in head and neck
carcinoma cells. Clin Cancer Res. 17:4425–4438. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Barsky SH, Siegal GP, Jannotta F and
Liotta LA: Loss of basement membrane components by invasive tumors
but not by their benign counterparts. Lab Invest. 49:140–147.
1983.PubMed/NCBI
|
|
13.
|
Liotta LA, Tryggvason K, Garbisa S, Hart
I, Foltz CM and Shafie S: Metastatic potential correlates with
enzymatic degradation of basement membrane collagen. Nature.
284:67–68. 1980. View
Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Caudroy S, Polette M, Tournier JM, et al:
Expression of the extracellular matrix metalloproteinase inducer
(EMMPRIN) and the matrix metalloproteinase-2 in bronchopulmonary
and breast lesions. J Histochem Cytochem. 47:1575–1580. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Polette M, Gilles C, Marchand V, et al:
Tumor collagenase stimulatory factor (TCSF) expression and
localization in human lung and breast cancers. J Histochem
Cytochem. 45:703–709. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Muraoka K, Nabeshima K, Murayama T, Biswas
C and Koono M: Enhanced expression of a tumor-cell-derived
collagenase-stimulatory factor in urothelial carcinoma: its
usefulness as a tumor marker for bladder cancers. Int J Cancer.
55:19–26. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Rosenthal EL, Shreenivas S, Peters GE,
Grizzle WE, Desmond R and Gladson CL: Expression of extracellular
matrix metalloprotease inducer in laryngeal squamous cell
carcinoma. Laryngoscope. 113:1406–1410. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Li R, Huang L, Guo H and Toole BP: Basigin
(murine EMMPRIN) stimulates matrix metalloproteinase production by
fibroblasts. J Cell Physiol. 186:371–379. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Sameshima T, Nabeshima K, Toole BP, et al:
Glioma cell extracellular matrix metalloproteinase inducer
(EMMPRIN) (CD147) stimulates production of membrane-type matrix
metalloproteinases and activated gelatinase A in co-cultures with
brain-derived fibroblasts. Cancer Lett. 157:177–184. 2000.
View Article : Google Scholar
|
|
20.
|
Guo H, Zucker S, Gordon MK, Toole BP and
Biswas C: Stimulation of matrix metalloproteinase production by
recombinant extracellular matrix metalloproteinase inducer from
transfected Chinese hamster ovary cells. J Biol Chem. 272:24–27.
1997. View Article : Google Scholar
|
|
21.
|
Jin JS, Wu CY, Lin YF, et al: Higher
expression of epidermal growth factor receptor is associated with
extracellular matrix metalloprotease inducer in colorectal
adenocarcinoma: tissue microarray analysis of immunostaining score
with clinicopathological parameters. Dis Markers. 22:309–316. 2006.
View Article : Google Scholar
|
|
22.
|
Menashi S, Serova M, Ma L, Vignot S,
Mourah S and Calvo F: Regulation of extracellular matrix
metalloproteinase inducer and matrix metalloproteinase expression
by amphiregulin in transformed human breast epithelial cells.
Cancer Res. 63:7575–7580. 2003.
|
|
23.
|
Toulany M, Dittmann K, Baumann M and
Rodemann HP: Radiosensitization of Ras-mutated human tumor cells in
vitro by the specific EGF receptor antagonist BIBX1382BS. Radiother
Oncol. 74:117–129. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Takahashi M, Suzuki S and Ishikawa K:
Cyclophilin A-EMMPRIN interaction induces invasion of head and neck
squamous cell carcinoma. Oncol Rep. 27:198–203. 2012.PubMed/NCBI
|
|
25.
|
Rubin Grandis J, Melhem MF, Gooding WE, et
al: Levels of TGF-alpha and EGFR protein in head and neck squamous
cell carcinoma and patient survival. J Natl Cancer Inst.
90:824–832. 1998.
|
|
26.
|
Ang KK, Berkey BA, Tu X, et al: Impact of
epidermal growth factor receptor expression on survival and pattern
of relapse in patients with advanced head and neck carcinoma.
Cancer Res. 62:7350–7356. 2004.PubMed/NCBI
|
|
27.
|
Gupta AK, McKenna WG, Weber CN, et al:
Local recurrence in head and neck cancer: relationship to radiation
resistance and signal transduction. Clin Cancer Res. 8:885–892.
2002.PubMed/NCBI
|
|
28.
|
Suzuki S, Sato M, Senoo H and Ishikawa K:
Direct cell-cell interaction enhances pro-MMP-2 production and
activation in co-culture of laryngeal cancer cells and fibroblasts:
involvement of EMMPRIN and MT1-MMP. Exp Cell Res. 293:259–266.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Hanata K, Yamaguchi N, Yoshikawa K, et al:
Soluble EMMPRIN (extra-cellular matrix metalloproteinase inducer)
stimulates the migration of HEp-2 human laryngeal carcinoma cells,
accompanied by increased MMP-2 production in fibroblasts. Arch
Histol Cytol. 70:267–277. 2007. View Article : Google Scholar
|
|
30.
|
Bordador LC, Li X, Toole B, et al:
Expression of emmprin by oral squamous cell carcinoma. Int J
Cancer. 85:347–352. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Sweeny L, Liu Z, Bush BD, Hartman Y, Zhou
T and Rosenthal EL: CD147 and AGR2 expression promote cellular
proliferation and metastasis of head and neck squamous cell
carcinoma. Exp Cell Res. 318:1788–1798. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Nicholson RI, Gee JM and Harper ME: EGFR
and cancer prognosis. Eur J Cancer. 37(Suppl 4): S9–S15. 2001.
View Article : Google Scholar
|
|
33.
|
Laskin JJ and Sandler AB: Epidermal growth
factor receptor: a promising target in solid tumours. Cancer Treat
Rev. 30:1–17. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Tang X, Guo N, Xu L, Gou X and Mi M:
CD147/EMMPRIN: an effective therapeutic target for hepatocellular
carcinoma. J Drug Target. 21:224–231. 2012. View Article : Google Scholar
|
|
35.
|
Yang X, Zhang P, Ma Q, et al: EMMPRIN
silencing inhibits proliferation and perineural invasion of human
salivary adenoid cystic carcinoma cells in vitro and in vivo.
Cancer Biol Ther. 13:85–91. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
37.
|
Sok JC, Coppelli FM, Thomas SM, et al:
Mutant epidermal growth factor receptor (EGFRvIII) contributes to
head and neck cancer growth and resistance to EGFR targeting. Clin
Cancer Res. 12:5064–5073. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Goerner M, Seiwert TY and Sudhoff H:
Molecular targeted therapies in head and neck cancer - an update of
recent developments. Head Neck Oncol. 2:82010. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Cassell A and Grandis JR: Investigational
EGFR-targeted therapy in head and neck squamous cell carcinoma.
Expert Opin Investig Drugs. 19:709–272. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Wheeler SE, Suzuki S, Thomas SM, et al:
Epidermal growth factor receptor variant III mediates head and neck
cancer cell invasion via STAT3 activation. Oncogene. 29:5135–5145.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Bhola NE, Thomas SM, Freilino M, et al:
Targeting GPCR-mediated p70S6K activity may improve head and neck
cancer response to cetuximab. Clin Cancer Res. 17:4996–5004. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Tian L, Zhang Y, Chen Y, Cai M, Dong H and
Xiong L: EMMPRIN is an independent negative prognostic factor for
patients with astrocytic glioma. PLoS One. 8:e580692013. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Zheng HC, Takahashi H, Murai Y, et al:
Upregulated EMMPRIN/CD147 might contribute to growth and
angiogenesis of gastric carcinoma: a good marker for local invasion
and prognosis. Br J Cancer. 95:1371–1378. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Reimers N, Zafrakas K, Assmann V, et al:
Expression of extracellular matrix metalloproteases inducer on
micrometastatic and primary mammary carcinoma cells. Clin Cancer
Res. 10:3422–3428. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Nakamura K, Kodama J, Hongo A and
Hiramatsu Y: Role of EMMPRIN in endometrial cancer. BMC Cancer.
12:1912012. View Article : Google Scholar : PubMed/NCBI
|
